Pfizer Inc. $PFE Stock Acquired by Welch Group LLC

Welch Group LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 3.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,271,062 shares of the biopharmaceutical company’s stock after purchasing an additional 76,437 shares during the period. Pfizer makes up approximately 2.2% of Welch Group LLC’s investment portfolio, making the stock its 18th biggest holding. Welch Group LLC’s holdings in Pfizer were worth $64,771,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Bank of America Corp DE acquired a new stake in Pfizer in the second quarter valued at approximately $1,049,602,000. BlackRock Inc. increased its holdings in Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares in the last quarter. Nykredit A S purchased a new stake in Pfizer during the 2nd quarter worth approximately $205,774,000. Assenagon Asset Management S.A. raised its holdings in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after acquiring an additional 5,829,204 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after acquiring an additional 5,501,032 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. Scotiabank boosted their price target on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Cantor Fitzgerald upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.65.

Pfizer Stock Down 0.1%

Shares of PFE opened at $30.48 on Monday. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $30.67. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a fifty day simple moving average of $28.55 and a two-hundred day simple moving average of $26.79. The company has a market capitalization of $173.73 billion, a PE ratio of 40.11, a price-to-earnings-growth ratio of 2.07 and a beta of 0.31.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the company posted $0.78 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.